uBriGene and Cellinfinity BIO to Advance In Vivo CAR-T Therapies
“We are excited about this strategic partnership with Cellinfinity BIO. In vivo CAR-T technologies have the potential to significantly reduce treatment costs,” said Dr. Sun Xiulian, Co-founder and CTO of uBriGene. “Leveraging our highly productive LVV Turbo™ lentiviral vector platform and GMP manufacturing expertise, we aim to lower the cost of goods for CAR-T therapies, improving patient accessibility and affordability.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.